2024
Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer
McNamara B, Demirkiran C, Hartwich T, Bellone S, Manavella D, Mutlu L, Greenman M, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. Gynecologic Oncology 2024, 183: 133-140. PMID: 38493021, DOI: 10.1016/j.ygyno.2024.01.028.Peer-Reviewed Original ResearchLow grade serous ovarian carcinomaWhole-exome-sequencingGain-of-function mutationsVS-4718Preclinical efficacyLow grade serous ovarian cancerSerous ovarian cancerControl-treated miceTumor growth inhibitionWild-type KRASLoss of heterozygosityDecreased p-ERKRAF/MEK inhibitionMedian survivalOvarian cancerRecurrence rateTherapeutic optionsOral gavageTumor growthTumor samplesIn vivo activityMAPK pathway genesRAF/MEK inhibitorsP-ERKEx vivo
2014
Ovulation and extra-ovarian origin of ovarian cancer
Yang-Hartwich Y, Gurrea-Soteras M, Sumi N, Joo WD, Holmberg JC, Craveiro V, Alvero AB, Mor G. Ovulation and extra-ovarian origin of ovarian cancer. Scientific Reports 2014, 4: 6116. PMID: 25135607, PMCID: PMC4137344, DOI: 10.1038/srep06116.Peer-Reviewed Original ResearchConceptsOvarian cancerExtra-ovarian originMalignant cellsChemokines/cytokinesOvarian surface epitheliumBetter prevention strategiesPotential molecular mechanismsFallopian tubeLate diagnosisOvarian localizationGastrointestinal tractSDF-1Mortality ratePrevention strategiesSurface epitheliumMain chemoattractantVivo modelLethal diseaseEx vivoCancerEarly detectionSpecific markersOvulationOvariesTumors